CYP2C8 polymorphism frequencies among malaria patients in Zanzibar

European Journal of Clinical Pharmacology

Volumn 61, Issue 1, 2005, Pages 15-18

  Cavaco, I ^b   Stromberg Norklit J ^a   Kaneko, A ^a   Msellem, M I ^c   Dahoma, M ^c   Ribeiro, V L ^b   Bjorkman, A ^a   Gil, J P ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF ALGARVE   (Portugal)

^c Ministry of Health Zanzibar   (Tanzania)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ANTIMALARIAL AGENT; CYTOCHROME P450 2C8;

AFRICAN AMERICAN; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; FEMALE; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALARIA; MALE; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TANZANIA; WILD TYPE;

ALLELES; AMODIAQUINE; ANTIMALARIALS; ARYL HYDROCARBON HYDROXYLASES; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALARIA, FALCIPARUM; MALE; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PREVALENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TANZANIA;

EID: 17644419314     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-004-0871-8     Document Type: Article

References (23)

1. Björkman A (2002) Malaria associated anaemia, drug resistance and antimalarial combination therapy. Int J Parasitol 32:1637-1643
2. White NJ, Looareesuwan S, Edwards G, Phillips RE, Karbwang J, Nicholl DD, Bunch C, Warrell DA (1987) Pharmacokinetics of intravenous amodiaquine. Br J Clin Pharmacol 23:127-135
3. Winstanley P, Edwards G, Orme M, Breckenridge A (1987) The disposition of amodiaquine in man after oral administration. Br J Clin Pharmacol 23:1-7
4. Li XQ, Bjorkman A, Andersson TB, Ridderstrom M, Masimirembwa CM (2002) Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther 300:399-407
5. Finta C, Zaphiropoulos PG (2000) The human CYP2C locus: a prototype for intergenic and exon repetition splicing events. Genomics 63:433-438
6. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, Goldstein JA (2001) Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11:597-607
7. Bahadur N, Leathart JB, Mutch E, Steimel-Crespi D, Dunn SA, Gilissen R, Houdt JV, Hendrickx J, Mannens G, Bohets H, Williams FM, Armstrong M, Crespi CL, Daly AK (2002) CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel6alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol 6:1579-1589
8. Nakajima M, Fujiki Y, Noda K, Ohtsuka H, Ohkuni H, Kyo S, Inoue M, Kuroiwa Y, Yokoi T (2003) Genetic polymorphisms of CYP2C8 in Japanese population. Drug Metab Dispos 31:687-690
9. Anonymous (2002) Zanzibar Malaria Control Program. National Guidelines for malaria diagnosis and treatment in Zanzibar
10. Olliaro P, Nevill C, LeBras J, Ringwald P, Mussano P, Garner P, Brasseur P (1996) Systematic review of amodiaquine treatment in uncomplicated malaria. Lancet 348:1196-1201
11. Schwartz E, Pener H, Issa SM, Golenser J (1997) An overview of the malaria situation in Zanzibar. J Community Health 22:33-44
12. Gil JP, Nogueira F, Stromberg-Norklit J, Lindberg J, Carrolo M, Casimiro C, Lopes D, Arez AP, Cravo PV, Rosario VE (2003). Detection of atovaquone and Malarone resistance conferring mutations in Plasmodium falciparum cytochrome b gene (cytb). Mol Cell Probes 17:85-89
13. Gardner MJ, Altman DG (1989) Statistics with confidence - confidence intervals and statistical guidelines. BMJ Publishing, London
14. Pang T (2003) Impact of pharmacogenomics on neglected diseases of the developing world. Am J Pharmacogenomics 3:393-398
15. Weise A, Grundler S, Zaumsegel D, Klotzek M, Grondahl B, Forst T, Pfutzner A (2004). Development and evaluation of a rapid and reliable method for cytochrome P450 2C8 genotyping. Clin Lab 50:141-148
16. Garcia-Martin E, Martinez C, Tabares B, Frias J, Agundez JA (2004) Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clin Pharmacol Ther 76:119-127
17. Mizutani T (2003) PM frequencies of major CYPs in Asians and Caucasians. Drug Metab Rev 35:99-106
18. Yasar U, Lundgren S, Eliasson E, Bennet A, Wiman B, de Faire U, Rane A (2002). Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem Biophys Res Commun 299:25-28
19. Scordo MG, Aklillu E, Yasar U, Dahl ML, Spina E, Ingelman-Sundberg M (2001) Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol 52:447-450
20. Allabi AC, Gala JL, Desager JP, Heusterspreute M, Horsmans Y (2003) Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. Br J Clin Pharmacol 56:653-657
21. Jewell H, Maggs JL, Harrison AC, O'Neill PM, Ruscoe JE, Park BK (1995) Role of hepatic metabolism in the bioactivation and detoxification of amodiaquine. Xenobiotica 25:199-217
22. Clarke JB, Neftel K, Kitteringham NR, Park BK (1991) Detection of antidrug IgG antibodies in patients with adverse drug reactions to amodiaquine. Int Arch Allergy Appl Immunol 95:369-375
23. Tingle MD, Jewell H, Maggs JL, O'Neill PM, Park BK (1995) The bioactivation of amodiaquine by human polymorphonuclear leucocytes in vitro: chemical mechanisms and the effects of fluorine substitution. Biochem Pharmacol 50:1113-1119